Search

Your search keyword '"Harada, Noriko"' showing total 21 results
Start Over Author "Harada, Noriko" Search Limiters Full Text
21 results on '"Harada, Noriko"'

8. Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study

Author

Kario, Kazuomi, primary, Okada, Kenta, additional, Murata, Mitsunobu, additional, Suzuki, Daisuke, additional, Yamagiwa, Kayo, additional, Abe, Yasuhisa, additional, Usui, Isao, additional, Tsuchiya, Norihiro, additional, Iwashita, Chie, additional, Harada, Noriko, additional, Okawara, Yukie, additional, Ishibashi, Shun, additional, and Hoshide, Satoshi, additional

Published
2020
Full Text
View/download PDF

9. Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study

Author

Akazawa, Manabu, Mimura, Wataru, Togo, Kanae, Ebata, Nozomi, Harada, Noriko, Murano, Haruka, Abraham, Lucy, and Fujii, Koichi

Subjects
osteoarthritis, chronic low back pain, opioid, non-steroidal anti-inflammatory drugs, pain, Journal of Pain Research, human activities, humanities, Original Research
Abstract

Manabu Akazawa,1 Wataru Mimura,1 Kanae Togo,2 Nozomi Ebata,3 Noriko Harada,4 Haruka Murano,5 Lucy Abraham,6 Koichi Fujii31Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan; 2Corporate Affairs, Health & Value, Pfizer Japan Inc., Tokyo, Japan; 3Medical Affairs, Pfizer Japan Inc., Tokyo, Japan; 4Clinical Research, Pfizer R&D Japan G.K., Tokyo, Japan; 5Clinical Research Professionals, Clinical Study Support Inc., Nagoya, Japan; 6Patient & Health Impact, Pfizer Ltd., Surrey, UKPurpose: Musculoskeletal diseases, including osteoarthritis (OA) and low back pain (LBP), are the leading causes of years lived with disability, and are associated with lowered quality-of-life, lost productivity, and increased healthcare costs. However, information publicly available regarding the Japanese real-world usage of prescription medications is limited. This study aimed to describe the clinical characteristics of patients with OA and chronic LBP (CLBP), and to investigate the patterns of medications and opioid use in Japanese real-world settings.Materials and methods: A retrospective study was conducted using a Japanese administrative claims database between 2013 and 2017. The outcomes were patient characteristics and prescription medications, and they were evaluated separately for OA and CLBP.Results: The mean age of 118,996 patients with OA and 256,402 patients with CLBP was 68.8±13.1 years and 64.8±16.4 years, respectively. Approximately 90% of patients with OA and CLBP were prescribed non-steroidal anti-inflammatory drugs (NSAIDs). Other prescriptions included hyaluronate injection (35.6%), acetaminophen (21.4%), and steroid injection (20.0%) in patients with OA, and pregabalin (39.0%) and acetaminophen (22.4%) in patients with CLBP. Weak opioids were prescribed to 10.7% and 20.6% of patients with OA and CLBP, respectively. The prescription of COX-2 inhibitors (OA: +6.5%; CLBP: +6.7%) and acetaminophen (OA: +16.4%; CLBP: +14.4%) increased between 2013 and 2017. The first commonly prescribed medication among patients with OA and CLBP were NSAIDs; hyaluronate injection (patients with OA) and pregabalin (patients with CLBP) were also common first-line medications. Acetaminophen, steroid injection (patients with OA), and weak opioids were prescribed more in the later phases of treatment.Conclusion: Most patients were prescribed limited classes of pain drugs, with NSAIDs being the most common pain medication in Japan for patients with OA and CLBP. Opioid prescription was uncommon, and were weak opioids when prescribed.Keywords: osteoarthritis, chronic low back pain, non-steroidal anti-inflammatory drugs, opioid, pain

Published
2019

10. Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study

Author

Akazawa,Manabu, Mimura,Wataru, Togo,Kanae, Ebata,Nozomi, Harada,Noriko, Murano,Haruka, Abraham,Lucy, Fujii,Koichi, Akazawa,Manabu, Mimura,Wataru, Togo,Kanae, Ebata,Nozomi, Harada,Noriko, Murano,Haruka, Abraham,Lucy, and Fujii,Koichi

Abstract

Manabu Akazawa,1 Wataru Mimura,1 Kanae Togo,2 Nozomi Ebata,3 Noriko Harada,4 Haruka Murano,5 Lucy Abraham,6 Koichi Fujii31Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan; 2Corporate Affairs, Health & Value, Pfizer Japan Inc., Tokyo, Japan; 3Medical Affairs, Pfizer Japan Inc., Tokyo, Japan; 4Clinical Research, Pfizer R&D Japan G.K., Tokyo, Japan; 5Clinical Research Professionals, Clinical Study Support Inc., Nagoya, Japan; 6Patient & Health Impact, Pfizer Ltd., Surrey, UKPurpose: Musculoskeletal diseases, including osteoarthritis (OA) and low back pain (LBP), are the leading causes of years lived with disability, and are associated with lowered quality-of-life, lost productivity, and increased healthcare costs. However, information publicly available regarding the Japanese real-world usage of prescription medications is limited. This study aimed to describe the clinical characteristics of patients with OA and chronic LBP (CLBP), and to investigate the patterns of medications and opioid use in Japanese real-world settings.Materials and methods: A retrospective study was conducted using a Japanese administrative claims database between 2013 and 2017. The outcomes were patient characteristics and prescription medications, and they were evaluated separately for OA and CLBP.Results: The mean age of 118,996 patients with OA and 256,402 patients with CLBP was 68.8±13.1 years and 64.8±16.4 years, respectively. Approximately 90% of patients with OA and CLBP were prescribed non-steroidal anti-inflammatory drugs (NSAIDs). Other prescriptions included hyaluronate injection (35.6%), acetaminophen (21.4%), and steroid injection (20.0%) in patients with OA, and pregabalin (39.0%) and acetaminophen (22.4%) in patients with CLBP. Weak opioids were prescribed to 10.7% and 20.6% of patients with OA and CLBP, respectively. The prescription of COX-2 inhibitors (OA: +6.5%; CLBP: +6.7%) and acetaminophen (OA: +16.4

Published
2019

14. A Study on Anxiety of Skate Beginners

Author

Nunome, Yasunori, Tazaki, Kentaro, KAWAI, Toshinobu, Takano, Satoshi, Yorikane, Yoshinori, Sakata, Isao, YAMADA, Yukio, SAGA, Hitoshi, Saito, Taketoshi, Minami, Takahisa, Tsukahara, Masao, Harada, Noriko, and Nakajima, Setsuko

Published
1995

17. Antibiotic Susceptibility Patterns as Aids in Classification and Characterization of Gram-negative Anaerobic Bacilli

Author

Finegold, Sydney M., Harada, Noriko E., and Miller, Lawrence G.

Abstract

Patterns of susceptibility of gram-negative anaerobic bacilli to antibiotics have been found to be distinctive and of significant help in classification and identification. Five major groups of gram-negative anaerobic bacilli have been defined on the basis of morphological and biochemical criteria. Antibiotic sensitivity patterns conform to these groupings and provide additional taxonomic criteria. The Bacteroides fragilisgroup is resistant to penicillin G, whereas the other groups are generally sensitive. B. fragilisstrains are relatively sensitive to erythromycin, whereas the Sphaerophorus necrophorusgroup is resistant. B. melaninogenicusstrains, B. oralis, and Fusobacteriumare all more sensitive to kanamycin and neomycin than the other two groups. Kanamycin is more active against Fusobacteriumstrains than neomycin, but less active against all other groups. Colistin or polymyxin B is useful for distinguishing between the resistant B. fragilisand the sensitive S. necrophorus. Antibiotic susceptibility determinations may be more readily performed in clinical laboratories than certain biochemical tests recommended for differentiation of the gram-negative anaerobic bacilli and may serve as helpful adjuncts to morphological and biochemical observations in classifying and characterizing these organisms. The use of standardized procedures for antibiotic susceptibility tests is essential if comparable results are to be obtained in different laboratories.

Published
1967
Full Text
View/download PDF

21. Time-Space Network Hypertension in the Digital Era　- Update From Jichi Medical University Hypertension Study.

Author

Kario K, Tomitani N, Harada N, Fujiwara T, and Hoshide S

Abstract

Time-space network hypertension is a data science approach that connects diverse information related to hypertension within a time-space framework. This field of academic research aims to predict disease onset and direct effective, individualized, optimized treatments by integrating and analyzing the variability of multiple internal biological and external environmental signals as they relate to blood pressure variability across different time phases. By linking time series changes in blood pressure and biological distribution with multi-environmental and physiological information, enabled by advances in digital technology, the time-space network hypertension approach contributes to "digital hypertension" research. This article from Jichi Medical University provides an update on research relating to the time-space network hypertension approach, which is designed to progress hypertension management towards achieving net zero cardiovascular events.

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results